A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy

Undersea and Hyperbaric Medicine

Volumn 33, Issue 1, 2006, Pages 33-43

  Heys, S D ^a   Smith, I C ^a   Ross, J A S ^a   Gilbert, F J ^a   Brooks, J ^a   Semple, S ^a   Miller, I D ^a   Hutcheon, A ^a   Sarkar, T ^a   Eremin, O ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CAPILLARY PERMEABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERBARIC OXYGEN; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAPILLARY PERMEABILITY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERBARIC OXYGENATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; VINCRISTINE;

EID: 33645878937     PISSN: 10662936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Schootman M, Jeffe D, Reschke A, Aft R. The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat 2004;2815-3:1-4.
2. Heys SD, Eremin JM, Sarkar TK, Hutcheon AW, Ah-See A, Eremin O. Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 1994; 179:493 -504.
3. Heys SD, Sarkar TK, Ah-See AK, Eremin J M, Brittenden J, Eremin O. Multimodality treatment in the management of locally advanced beast cancer. J Roy Coll Surg Ed 1993;38:9-15.
4. Eltahir A, Heys SD, Hutcheon AW et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998;175:127-132.
5. Anderson EDC, Forrest APM, Hawkins RA, Anderson TJ, Leonard RC, Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer 1991;63:561-566.
6. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst 1990:82:1539-1545.
7. Smith IE, Jones AL, O'Brien MER et al. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993 ;29a: 1796-1799.
8. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-429.
9. Fletcher GH. Radiation and drug resistance of breast cancer. Am J Clin Oncol 1984;7:617-624.
10. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 1993;26:631-636.
11. Wheeler R, Dirks J, Lunardi I, Nemiroff M. Effect of hyperbaric oxyen on the cytotoxicity of adriamycin and nitrogen mustard in cultured Burkitt's lymphoma cells. Cancer Res 1979;39:370-375
12. Teicher BA, Crawford JM, Holden SA, Cathcart KN. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of mephelan antitumor activity. Cancer Res 1987;47:5036-41.
13. Teicher BA, Herman TB, Holden BA, Cathcart KN. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Cancer Chemother Pharmacol 1988; 21: 286-91.
14. Teicher B, Holden B, Cathcart K, Herman T. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice. J Natl Cancer Inst 1988: 80: 599-603.
15. Cohen A, Weg N, Fanning GL et al. The effect of high pressure oxygen and nitrogen mustard on the Ehrlichs ascites tumor. Arch Surg 1966;93:638-42.
16. Krementz ET, Knudsen L. The effect of increased oxygen tension on the tumoricidal effect of nitrogen mustard. Surgery 1961:50:266-73.
17. Takenaka B, Arimura T, Higashi M, Nagayama T. Experimental study of bleomycin therapy in combination with hyperbaric oxygenation. Nippon Gan Chiryo Gakkai Shi 1980;15:864-75.
18. DeCosse JJ, Rogers LS. Influence of high pressure oxygen and chemotherapy on the AMel 4 hamster melanoma. Cancer Res 1966:26:287-92.
19. Leather RP, Eckert C. Hyperbaric oxygenation and mechlorethamine effectiveness. Arch Surg 1963;87:144-7.
20. Akiya T, Nakada T, Katayama T, Ota K, Chikenji M, Matsushita T, Saito H. Hyperbaric oxygenation for experimental bladder tumor. II. Hyperbaric oxygenation in combination with chemotherapy in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumors. Eur Urol 1988:14:150-5.
21. Monstrey SJ, Mullick P, Narayanan K, Ramasastry SS. Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 38: 163-8. 1997.
22. Upton PG, Yamaguchi KT, Myers S, Kidwell TP, Anderson RJ. The effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicicn skin toxicity in the rat. Cancer Treat Rep 1987;70:503-507.
23. Dische S. What have we learned from hyperbaric oxygen? Radiother Oncol 1991;20 Suppl; 1:71-74.
24. Dische S. Hyperbaric oxygen: The Medical Research Council trials and their significance. Brit J Radiol 1979,51:888-894
25. Marx RE, Ehler WJ, Tayaongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis in irradiated tissue. Am J Surg 1990; 160:519-524.
26. Marx RE. Radiation injury to tissue. In: Hyperbaric Medicine Practice. 1st ed. Kindwall EP (Ed). Best Publishing Company. Flagstaff AZ. 1995:447-503.
27. FeldmeierJ,CarlU,HartmannK, SminiaP.Hyperbaric oxygen: does it promote growth or recurrence of malignancy. Undersea Hyperb Med 2003;30:1-18.
28. Alagoz T, Buller RE, Anderson B et al. Evaluation of hyperbaric oxygen as a chemosensitiser in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer 1995;75:2313-22.
29. Stephenson R, MacKenzie I, Watt SJ, Ross JA. Measurement of oxygen concentration in delivery systems used for hyperbaric oxygen therapy. Undersea Hyperb Med 1996; 23: 185-188.
30. Miller AB, Hoogstraten B, Staquet M, Wrinkler A. Reporting Results of Cancer Treatment. Cancer 1981;47:207-214.
31. Brittenden J, Heys SD, Miller I, et al. Dietary supplementation with L-arginine in patients with breast cancer (>p;4cm) receiving multimodality treatment: report of a feasibility study. Br J Cancer 1994;69:918-921.
32. Gilbert FJ, Brookes JA, Staff RT, et al. Assessing dynamic contrast enhanced MRI as a method of measuring the effect of hyperbaric oxygen on breast cancer. Proceedings of the Seventh Meeting of the International Society for Magnetic Resonance in Medicine, Philadelphia, PA, May 22- 28, 1999;2:1081.
33. Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of Tl measurement in dynamic contrast-enhanced breast MRI using two- and three- dimensional variable flip angle fast low-angle shot. J Magn Reson Imaging 1999;9:163-71.
34. Tofts PS, Brix G, Buckley DL, Eveloch JL, Henderson E, Knopp M, Larsson HBW, Lee T- Y, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced Tl-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
35. Bottini A, Berruti A, Bersiga A, et al. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 2002;8:1816-1821.
36. Ogston KN. Miller ID. Payne S. et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast.2003;320-7.
37. Nylander G, Lewis D, Nordstrom H, Larsson J. Reduction of postischemic edema with hyperbaric oxygen. Plast Reconstr Surg 1985;76:596-603.
38. 2 in the management of crush injuries: a randomized double blind placebo- controlled clinical trial.J Trawwa l996;41:333-339.
39. Pritchard J, Anand P, Broome J, et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation induced brachial plexopathy. Radiother Oncol 2001;58:279-286.
40. Carl UM, Hartman KA. Hyperbaric oxygen for symptomatic breast edema after radiation therapy. Undersea Hyperb Med 1998; 25: 233-4.
41. 2 oxygen therapy for late sequelae in women receiving radiation after breast conserving surgery. Int J Radiat Oncol Biol Phys 2001;49:1029-31.
42. Sterk S, Schrier LM. Effects of exposure to hyperxia in operational diving. Proceedings of the XIth annual meeting of the European Undersea Biomedical Society. FOAReport C50021 -H1. ISSN 0347-7665 Ornhagen H, (ed). National Defence Research Insitute, Sweden. 1985; 123-131.
43. Phillips M, Cataneo MA, Ditkoff BA, et al. Volatile markers of breast cancer in the breath. Breast J 2003;9:184-191.
44. Stuhr LE, Iversen VV, Straume O, Maehle BO, Reed RK. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 2004; 210:35-40.
45. Petre PM, Baciewicz FA Jr, Tigan S, Spears JR. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Cardiovasc Surg 2003; 125:85-95.
46. Beppu T, Kamada K, Nakamura R, et al. A phase II study of radiotherapy after hyperbaric oxygenation combined with interfern-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. J Neurooncol 2003; 61:161-170.
47. 2 with chemotherapy for high grade gliomas. Radiother Oncol 2003;67:63- 67.